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Oxaliplatin and 5-fluorouracil have a significant activity in locally advanced oesophageal squamous cell cancer (OSCC). However, their
optimal dosage and efficacy when combined with concurrent radiotherapy as neoadjuvant treatment are unknown. This
non-randomised, phase I/II study aimed to define the maximum tolerated dose (MTD) and assessed the histopathological tumour
response rate to neoadjuvant oxaliplatin in weekly escalating doses (40, 45, 50mgm
 2) and continuous infusional 5-fluorouracil
(CI-5FU; 225mgm
 2) plus concurrent radiotherapy. Patients had resectable OSCC. Resection was scheduled for 4–6 weeks after
chemoradiotherapy. During phase I (dose escalation; n¼19), weekly oxaliplatin 45mgm
 2 plus CI-5FU 225mgm
 2 was established
as the MTD and was the recommended dosage for phase II. Oesophageal mucositis was the dose-limiting toxicity at higher doses.
During phase II, histopathological responses (o10% residual tumour cells within the specimen) were observed in 10 of 16 patients
(63%; 95% confidence interval: 39–82%). Overall, 16 of the 25 patients (64%) who underwent resection had a histopathological
response; tumour-free resection (R0) was achieved in 80%. Neoadjuvant weekly oxaliplatin 45mgm
 2 plus CI-5FU 225mgm
 2 with
concurrent radiotherapy provides promising histological response rates and R0 resection rates in locally advanced OSCC.
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Although the best treatment strategy for locally advanced
oesophageal squamous cell cancer (OSCC) is still being debated,
the use of neoadjuvant chemoradiotherapy has gained acceptance
(Gebski et al, 2007; Tepper et al, 2008). The rationale for
chemoradiotherapy followed by surgery is potentially to downsize
the tumour, thereby increasing the rate of tumour-free (R0)
resections, reducing early relapses and improving survival. Overall,
the impact of pre-operative treatment on survival depends on
achieving a major pathological response at oesophagectomy
(Swisher et al, 2005; Bru ¨cher et al, 2006). Pathological complete
responses are associated with improved long-term survival but
occur in only 20–40% of patients after pre-operative chemo-
radiotherapy (Bates et al, 1996; Walsh et al, 1996; Bosset et al,
1997; Ajani et al, 2001).
The most widely used pre-operative chemoradiotherapy combi-
nation – cisplatin and 5-fluorouracil (5FU) with concurrent
radiotherapy – has failed to achieve a histopathological complete
response rate above 30% or a long-term survival rate higher than
40% in patients with OSCC. Besides limited efficacy, this regimen is
associated with substantial gastrointestinal toxicities, including
nausea, mucositis and oesophagitis (Herskovic et al, 1992; Al-Sarraf
et al, 1997). To enhance the efficacy and tolerability of multimodal
treatment, new chemotherapeutic agents, such as oxaliplatin, have
been incorporated into oesophageal cancer therapy.
Oxaliplatin is a potent radiosensitising agent both in vitro and in
clinical practice (Blackstock et al, 1999; Cividalli et al, 2002;
McMullen and Blackstock, 2002; Magne et al, 2003), and phase I
and II trials suggest that it is at least as effective as cisplatin in
OSCC whereas being better tolerated (Khushalani et al, 2002). If
the goal of preoperative radiochemotherapy is to maximise tumour
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sshrinkage before surgery, chemotherapy should be scheduled as
dense as possible (that is, applied concomitantly and as often as
possible during RT), to optimise local effects by sensitising tumour
cells to radiation. The use of a weekly oxaliplatin schedule may, in
addition, reduce acute toxicity and maximise the inhibition of sub-
lethal radiation-induced DNA damage repair (Aschele et al, 2005).
Addition of weekly oxaliplatin to continuous 5-FU or capecitabine
and concomitant radiotherapy has been shown to be feasible and
active in phase I and II studies in rectal cancer (Machiels et al,
2005; Rutten et al, 2006, Ro ¨del et al, 2007). Moreover, the weekly
application of oxaliplatin plus infusional 5FU/folinic acid has also
proven to be highly active in first-line metastatic colorectal
(Porschen et al, 2007) and gastric cancer (Lordick et al, 2005). Of
note, this regimen is also associated with an acceptable toxicity
profile with a particularly low rate of sensory neuropathy (Grothey
et al, 2002). Consequently, we conducted this study to define the
maximum tolerated dose (MTD) of weekly oxaliplatin with
continuous infusional 5FU (CI-5FU) plus concurrent radiotherapy
in OSCC, and to assess the clinical activity at the recommended
dose level (RDL).
MATERIALS AND METHODS
This multicentre study was conducted at two institutions in
Germany. The protocol was approved by the local ethics
committee and the study was performed in accordance with the
Declaration of Helsinki. All patients provided written informed
consent.
In the phase I and II portion, patients (aged 18–70 years) with
histologically confirmed, locally advanced, non-metastatic OSCC
(cT2–4 N0–Nþ M0) were eligible. All were candidates for
curative surgery, with a Bartel score o21 (Bartels et al, 1998), no
prior chemotherapy or radiotherapy and adequate organ function.
Exclusion criteria included: oesophageal stent implantation,
tracheobronchial tree invasion, tracheobronchial fistula, a second
malignancy, uncontrolled infection, neuropathy grade 41o r
congestive heart failure of New York Heart Association grade X2.
Study design
This was an open-label, non-randomised, phase I/II study.
Initially, at least three patients were entered at each dose level
(DL). Toxicities were recorded at each DL using the National
Cancer Institute Common Toxicity Criteria version 2.0. A dose-
limiting toxicity (DLT) was defined as any adverse event (AE) of
grade X3 clearly related to chemoradiotherapy. If no DLT was
found, dose escalation was permitted. If any DLT occurred in the
first three patients, three additional patients were treated at the
same dose. If a DLT was then noted in one or more patients, no
further dose escalation was permitted. The MTD was the highest
dose at which fewer than two out of six patients experienced DLTs
during chemoradiotherapy and/or in the immediate pre-operative
phase. This DL was chosen as the RDL for phase II.
Treatment plan
Chemotherapy consisted of escalating doses of weekly oxaliplatin
(DL 1: 40mgm
 2;D L2 :4 5 m g m
 2;D L3 :5 0 m g m
 2 (Figure 1
Flow diagram); Supplementary Table A and Supplementary Figure
A). Oxaliplatin was administered by intravenous infusion over 2h
every week for 5 weeks, and CI-5FU 225mgm
 2 was administered
by 24-h continuous infusion on days 1–33.
Radiotherapy was administered for 5 days every week for
5 weeks at a dose of 1.8Gy/day to the isocentre or a normalisation
point that was representative of the target volume, up to a total
dose of 45Gy.
3D conformal external-beam radiotherapy with 6–15MeV
photons was delivered using three- and four-field techniques.
The clinical target volume (CTV) comprised the primary tumour
and adjacent lymph nodes with a margin of 4cm in the cranio-
caudal direction. For cervical cancers the cervical lymph nodes up
to the hyoid including the medial part of the paraclavicular lymph
nodes had to be included. For tumours in the mid oesophagus
lymph nodes in the upper anterior and posterior mediastinum
were included in the CTV if they were suspicious for infiltration on
CT and/or endosonography. For tumours in the lower third lymph
nodes along the minor gastric curve and around the coeliac trunk
were enclosed if they were suspicious on imaging.
The margin of the planning target volume to the CTV was
8–10mm in all directions, taking internal organ movements as
well as set up errors into account (Supplementary Table B).
Surgery was scheduled for 4–6 weeks after completion of
chemoradiotherapy. Patients underwent standardised, trans-
thoracic, en-bloc oesophagectomy with two-field lymphadenec-
tomy (Siewert et al, 1998). Cervical tumours were treated with a
partial oesophageal resection and reconstruction was carried out
with a free jejunal graft (Steinau et al, 1988).
Patients were examined at 3, 6, 9 and 12 months and every
6 months thereafter. Assessment included physical examination,
laboratory investigations, endoscopy, abdominal ultrasonography
and computed tomography of the neck, chest and abdomen.
Treatment-related morbidity and mortality
Any complication occurring after surgery was considered as
postoperative morbidity, including clinically symptomatic anasto-
motic leakage, pulmonary, cardiovascular, infectious, and
miscellaneous events. The overall postoperative mortality rate
was defined as any death that occurred before a patient was
discharged or even after discharge if there was any possible
correlation with the operation itself.
Histopathological work-up
Response to chemoradiotherapy was classified by quantification of
residual tumour cells as follows: no residual tumour cells
(complete regression, ypCR); o10% viable tumour cells (subtotal
regression, ypSR); 10–50% viable tumour cells (partial regression,
ypPR); 450% viable tumour cells (minimal regression) (Becker
et al, 2003; Bru ¨cher et al, 2006). Histopathological response to
radiochemotherapy was defined as o10% residual tumour cells,
whereas histopathological non-response was defined as 410%
residual tumour.
Statistical analysis
The primary end point of the phase I part of the study was to
define the MTD for oxaliplatin and CI-5FU plus radiotherapy; the
primary objective of phase II was the histopathological response
rate, defined as a complete or a subtotal histopathological
response. The phase II study was designed as a Gehan two-stage
trial (Gehan, 1961), assuming a response rate of X50%. With
a power of 95%, a sample size of five was required for the first
stage. The sample size for the second stage was determined by
the observed number of responses and the pre-specified precision
of 10%.
Secondary study end points included clinical response rate,
tolerability, completeness of tumour resection (R0 resection vs R1
or R2 resection), ypT and ypN categories, operative mortality and
median overall survival (OS), event-free survival (EFS). OS and
EFS were analysed in the intent-to-treat population and were
calculated from the date of study assignment until death (OS) or
until documented radiological or endoscopic progression, death or
last contact (EFS). The probability of survival was estimated using
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sthe Kaplan–Meier method. As the response was defined by
histopathological findings available only after surgery, event time
analysis comparing histopathlogical responders and non-respon-
ders to neoadjuvant therapy was calculated from the day of
surgery. Comparisons between patient groups were made by a log-
rank test. The median survival and hazards ratio calculated by
Cox’s proportional hazards model were reported with 95%
confidence intervals (CIs). Median follow-up time was calculated
by the inverse Kaplan–Meier approach (Schemper and Smith,
1996). The Conditional Binomial Exact Test (Rice, 1988) was used
to compare frequencies between patient groups and 95%
confidence intervals for proportions were calculated according to
Brown (Brown et al, 2001). All statistical analyses were performed
at a 0.05 level of significance.
RESULTS
Patient characteristics
From July 2003 to July 2005, 29 patients were enroled (Table 1). All
patients received one or more doses of oxaliplatin and CI-5FU plus
radiation, and were assessed for response, toxicity and survival.
Dose escalation and DLTs
Seven patients were treated at DL 1. One of the first three patients
experienced grade 3 mucositis, meeting the criteria for a DLT.
Subsequently, four more patients were included, all of whom
completed chemoradiotherapy with no DLTs. Owing to simulta-
neous inclusion of two patients at different study sites, an
additional patient was enroled at DL 2; no DLTs were observed
in the first three patients. Two of the six patients treated at DL 3
developed grade 3 mucositis needing temporary parenteral
nutrition. Consequently, dose escalation was stopped and three
additional patients were treated at DL 2, the RDL, one of whom
developed grade 3 diarrhoea. Oxaliplatin 45mgm
 2 was therefore
selected as the MTD. The RDL cohort was increased to 16 patients
for the phase II study.
Treatment delivery
The median duration of treatment was 5 (range, 3–5) weeks.
Overall, 25 of 29 patients completed the planned treatment without
interruption; the other four patients did not complete the
treatment programme because of excessive toxicity.
Toxicity
Haematological AEs were mild in the phase I (Supplementary
Table C) and II studies (Table 2).
In phase I, one patient had grade 3 diarrhoea and three had
grade 3 mucositis. One patient was hospitalised with toxic colitis
and grade 3 diarrhoea. Two patients with oesophageal mucositis,
CI-5FU 225mg-m2 dl-33
+
RTX 1.8 Gy
–1d d1-33
All patients
n = 29
Oxaliplatin 40mg-m
2; n = 7
Oxaliplatin 45mg-m2; n = 16
Oxaliplatin 50mg-m2; n = 6
Surgical treatment
n = 25 (86%)
Excluded: (n=4)
-PD (n=2)
-PS ≥ 2 (n=1)
-refusal (n=1)
Histopathologic responders
16/25 = 64%
R0
15 of 16 (94%)
9 dead; 7 alive 9 dead
R0
5 of 9 (56%)
Histopathologic nonresponders
9 of 25 = 36%
+
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Figure 1 Flow diagram illustrating the study conduct and patient outcome according to histopathological response.
Table 1 Patient and tumour characteristics
Characteristics No. of patients (n¼29) %
Age (years)
Median 60
Range 19–67
Sex
Male 25 86
Female 4 14
ECOG performance status
02 1 7 2
18 2 8
Clinical stage
a
uT2 2 7
uT3 26 90
uT4 1 3
uN+ 29 100
Differentiation
Well differentiated (G1) 0 0
Moderately differentiated (G2) 10 35
Poorly differentiated (G3) 18 62
Undifferentiated (G4) 1 3
Tumour location
Cervical oesophagus 6 21
Mid thoracic 11 38
Lower thoracic 12 41
ECOG¼Eastern Cooperative Oncology Group.
aAs determined by endoscopic
ultrasonography.
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streated at dose level 3, were hospitalised for intravenous hydration
and nutrition.
Histopathological response
The histopathological response rate (ypCR and ypSR) among all
operated patients was 64% (16 of 25; 95%; CI: 43–82%). During
phase II, histopathological responses were observed in 10 of
16 patients treated at the RDL (63%, 95% CI: 45–80%). It is
interesting to note that two patients treated at the RDL could not
be operated because of disease progression and were therefore
considered histopathological non-responders.
Clinical response
After chemoradiotherapy, the overall response rate according to
RECIST was 45% (13 of 29 patients; 95% CI: 28.4–62.5%),
including three complete responses (10%; 95% CI: 3.6–26.4%); 14
patients had stable disease (48%; 95% CI: 31.4–65.6%) and two
patients had disease progression (7%; 95% CI: 1.9–22%). In the
phase II population (n¼16), eight patients (50%; 95% CI:
28–72%) achieved a response, including three complete remis-
sions. In one patient (6%) the disease progressed during treatment
(Supplementary Table D).
Surgery
Overall, 25 patients (86%) underwent surgery 4–6 weeks after
chemoradiotherapy. Four patients did not undergo surgery as a
result of disease progression (n¼2), deterioration in medical
fitness (n¼1) and patient refusal (n¼1). Among the operated
patients, 20 patients (80%) underwent R0 resection and five
patients (20%) underwent R1 resection. No deaths occurred
during surgery. The overall postoperative mortality rate was
12.0% (3 of 25 patients; one patient died because of a chylothorax,
one because of bleeding, and one because of mediastinitis)
(Table 3).
Histopathological responders had a significantly higher R0
resection rate (15 of 16 patients (94%); 95% CI: 71.6–98.8%) than
non-responders (5 of 9 patients (56%); 95% CI: 26.7–81.1%;
P¼0.023).
Survival
After a median follow-up of 33.5 months (range, 26.3–48.3
months) from date of study assignment, 7 of the 29 patients
(24%) were still alive, with no evidence of disease recurrence in six
patients (21%). Two patients developed locoregional, extraluminal
recurrences, five had distant recurrences and seven had simulta-
neous locoregional and distant recurrences.
The median OS was 18 months (95% CI: 15.8–19.4 months;
Supplementary Figure B), with an estimated 2-year survival rate of
28% (±8.3%).
The median EFS was 12.9 months (95% CI: 10.1–15.7 months;
Supplementary Figure C), with a 2-year EFS rate of 24% (±7.9%).
Comparison between histopathological responders (n¼16)
and non-responders (n¼9) shows a non-significant trend towards
a better OS (P (log-rank)¼0.21 Figure 2) and EFS (P (log-rank)¼
0.11; Figure 3) in responding patients.
RO resection (n¼20) was associated with a significantly
improved OS (P (log-rank)¼0.028) with a median OS of 16
months (95% CI: 8.7–23.3 months) vs 9.0 months in patients with
incomplete resection (n¼5; 95% CI: 6.8–11.1 months).
DISCUSSION
This phase I/II study demonstrated that a weekly regimen of
neoadjuvant oxaliplatin 45mgm
 2, CI-5FU 225mgm
 2 per day
plus concurrent radiotherapy is feasible and effective treatment for
patients with locally advanced OSCC, with 450% of resected
specimens showing major histopathological responses in the
primary tumour.
One episode of grade 3 diarrhoea represented the only DLT at
the RDL during the phase I dose-escalation study. Overall, clinical
toxicities, particularly grade 3/4 haematological and gastrointest-
inal events, were less intense than previously reported with 5-FU-
and cisplatin-based chemoradiotherapy (Bedenne et al, 2007).
Toxicity assessment in patients treated at the RDL during phase II
confirmed the excellent tolerability of the regimen, with mainly
mild AEs and only a 6% overall incidence of grade 3 mucositis and
diarrhoea (see Supplementary Table C). This rate of grade 3
mucositis did not exceed that reported previously for cisplatin-
based chemoradiotherapy (Heath et al, 2000). Neurotoxicity,
a potential concern because of the weekly oxaliplatin administra-
tion, consisted mainly of grade 1 events. These findings are compa-
rable with other phase I/II studies using oxaliplatin-based
Table 2 Haematological and non-haematological toxicities (National
Cancer Institute Common Toxicity Criteria, version 2.0) observed in the
phase II study
No. of patients (n¼16)
Toxicity grade 1 2 3 4 Total (%)
Haematological toxicity
Anaemia 9 1 — — 10 (63)
Neutropenia 4 1 — — 5 (31)
Febrile neutropenia ———— —
Thrombocytopenia 3 — — — 3 (19)
Non-haematological toxicity
Diarrhoea 5 1 1 — 8 (50)
Nausea 6 1 1 — 8 (50)
Emesis 7 2 — — 9 (56)
Mucositis within RT field 5 3 1 — 9 (56)
Mucositis outside RT field 1 — — — 1 (6)
Sensory neuropathy 6 2 — — 8 (50)
Cold-related dysaesthesias 2 1 — — 3 (19)
Hand-foot syndrome — — 1 — 1 (6)
Lethargy 10 3 — — 13 (81)
RT¼radiotherapy.
Table 3 Surgical outcome, post-operative morbidity and mortality
(n¼25)
Variable No. of patients %
Total resections 25 100
Type of resection
R0 20 80
R1 5 20
Total morbidity 23 92
Anastomotic leakage 12 48
Pulmonary complications 5 20
Necrosis of intestinal interponate 2 8
Bleeding 2 8
Chylothorax 1 4
Retrosternal abscess 1 4
Pleural empyema 1 4
Gastroparesis 1 4
Overall postoperative mortality rate 3 12
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schemoradiotherapy (Khushalani et al, 2002; Conroy et al,2 0 0 7 ) .T h e
favourable toxicity profile led to good compliance with treatment,
and the full radiation course was delivered to all but two patients,
and only four patients stopped chemotherapy because of toxicity.
However, a postoperative mortality rate of 12%, although it is in
line with data from previous studies in this disease (Stahl et al,
1996, 2005; Van Lanschot et al, 2001) could reflect an important
issue hampering satisfying long-term survival in this patient
population.
The histopathological response rate of 64% in all operated
patients (n¼25) and the histopathological response rate of 63%
observed during phase II (n¼16), compare favourably with
cisplatin-based neoadjuvant chemoradiotherapy (Bosset et al,
1997; Stahl et al, 2005; Bru ¨cher et al, 2006; Bedenne et al, 2007)
and oxaliplatin-based chemoradiotherapy given every 2 weeks
(Khushalani et al, 2002). This considerable activity may be a result
of enhanced radiosensitisation achieved through weekly oxalipla-
tin administration. Pathological response rates across phase II and
III trials vary significantly, so a randomised, comparative study
would be required before definitive conclusions can be made
regarding the superiority of this regimen over cisplatin-based
regimens.
The high histopathological response rate observed would be
expected to lead to a high R0 resection rate, which was 94% in the
histopathological responders compared with 56% in the histo-
pathological non-responders, confirming published data (Bru ¨cher
et al, 2006). Complete resection, including negative microscopic
margins, is a known positive prognostic factor in estimating the
survival of patients undergoing oesophagectomy (Kelsen et al,
2007). The overall rate of 80% for R0 resections reported here in
locally advanced disease compares favourably with previously
reported rates (Hofstetter et al, 2002; Mariette et al, 2003).
Histopathological response, together with nodal status, appears
to be the best predictor of outcomes after chemoradiotherapy
(Swisher et al, 2005). However, although the median survival of 18
months was in the range reported previously, the 2-year survival
rate of 28% observed here was suboptimal compared with survival
rates reported for cisplatin-based chemoradiotherapy regimens in
similar patient populations (Stahl et al, 2005; Bedenne et al, 2007).
Moreover, better survival rates were reported with an oxaliplatin-
containing chemoradiotherapy regimen in patients with inoperable
oesophageal cancer (Conroy et al, 2007). A possible explanation
for the relatively low observed 2-year survival rate could be the
rather short-term neoadjuvant treatment duration of only 5 weeks
in this trial. It is interesting to note that compared with The French
Multicenter Study (Bedenne et al, 2007) and the German trial
(Stahl et al, 2005) no induction chemotherapy before the start of
combined radiochemotherapy was administered. This indicates
that, although the current study included a thoroughly staged and
uniformly defined population, the optimal treatment for patients
presenting with locally advanced OSCC has not yet been defined.
The high number of distant relapses may have led to relatively low
survival rates and suggests that further refinement of the
chemotherapy regimen is warranted. Therefore, intensification of
the treatment regimen, for example, by performing a sequential
application of a high-dose induction chemotherapy followed by
radiochemotherapy, as investigated by Stahl et al (2005) could
provide a better control of systemic disease. Also, addition of other
chemotherapy drugs like taxanes may add some additional
effectiveness (Meluch et al, 2003; van de Schoot et al, 2008).
Overall, neoadjuvant chemoradiotherapy for locally advanced
OSCC may improve histopathological response and R0 resection
rates. Nevertheless, the impact of additional surgery on survival is
still being debated, with recent phase III trials failing to
demonstrate a consistent survival benefit over chemoradiotherapy
alone (Stahl et al, 2005; Bedenne et al, 2007).
In conclusion, weekly oxaliplatin, CI-5FU and conventionally
fractionated radiotherapy proved a feasible regimen with a
promising pathological response rate and a high R0 resection rate
in a uniform and well-staged group of patients with locally advanced
OSCC. However, due to a high distant relapse rate, the 2-year
survival rate in this patient population was rather disappointing.
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Figure 3 Event-free survival (EFS) by histopathological response (P (log-
rank)¼0.11). EFS is shown for all patients who underwent surgery
(n¼25). The median EFS from the date of surgery was 12 months in
histopathological responders (95% confidence interval (CI): 6.1–17.9
months) vs 9 months for non-responders (95% CI: 0.3–17.8 months).
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Figure 2 Survival by histopathological response (P (log-rank)¼0.21 vs
non-response). Survival is shown for all patients who underwent surgery
(n¼25). The median OS from date of surgery for histopathological
responders was 16 months (95% confidence interval (CI): 6.2–25.8
months), respectively, compared with 12 months (95% CI: 3.2–20.8
months) in histopathological non-responders, hazard ratio: 1.78 (95% CI:
0.70–4.57).
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sTo optimise treatment further, new targeted agents combined
with conventional cytotoxic therapy are being evaluated. In
particular, the activity of a weekly regimen of oxaliplatin plus
CI-5FU and radiotherapy with the addition of the epidermal
growth factor receptor inhibitor, cetuximab is currently being
investigated in a prospective phase II trial in locally advanced
OSCC.
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